COMPASS Pathways is recruiting patients for the clinical trial that aims to explore the efficacy and safety of COMP360 25 mg as compared to COMP360 1 mg (control condition) administered with psychological support in participants with Anorexia Nervosa.
The researchers plan that August 2022 will be the study start date. The indicative completion of the clinical trial will be expected in December 2023.
Among primary outcome measures are the Change from baseline in the Eating Disorder Examination (EDE) global score and The EDE is a structured clinical interview (investigator rated) used to measure severity of the characteristic psychopathology of eating disorders.
The page dedicated to this clinical trial can be found here: https://ichgcp.net/clinical-trials-registry/NCT05481736.